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ABSTRACT
CD24 is a glycosylphosphatidylinositol (GPI)-linked cell surface glycoprotein expressed in central nervous sys-
tem cells. Recent investigations have suggested that CD24 participates in the pathogenesis of experimental
autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). However, a limited number of
studies have been published regarding the contribution of CD24 to the risk and severity of MS in humans. We
investigated the contribution of a CD24 single nucleotide polymorphism (SNP) to MS disease risk and severity.
We also studied mRNA expression of the CD24 gene in Iranian MS patients using quantitative real-time poly-
merase chain reaction (PCR). Our findings showed that the CD24v/v genotype was significantly more frequent
in MS patients compared with controls (pc = .004). Moreover, a statistically significant difference in the Multi-
ple Sclerosis Severity Score (MSSS) was found between MS patients carrying CD24a/a and CD24v/v genotypes
(p = .008). The results also indicated that the expression of CD24 mRNA was 1.7 times more in MS patients
compared with controls. In conclusion, our results suggest that the CD24v/v genotype influences both MS dis-
ease risk and severity in Iranian MS patients, and the high disease severity in CD24v/v patients may indicate that
they require more aggressive treatment than do patients carrying CD24a/a.
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INTRODUCTION
Multiple sclerosis (MS) is the most common neurolog-
ical disease of the central nervous system (CNS) world-
wide, affecting 1/1,000 Caucasians (Noseworthy, Gold,
& Hartung, 1999). It is an autoimmune disorder medi-
ated by autoreactive T-cell responses to myelin antigens
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(Agrawal & Yong, 2007). The onset of MS is commonly
between 20 and 40 years of age, and its incidence among
women is almost twice that of men (Dean, 1994). The
etiology of MS remains elusive, but there is evidence
that both genetic and environmental factors play roles
in disease susceptibility (Oksenberg, Bernini, Barcellos,
& Hauser, 2001). Numerous epidemiological studies
have shown that there is an increased risk of MS among
MS relatives (Robertson et al., 1997; Sadovnick, Ebers,
Dyment, & Risch, 1996). Moreover, twin studies in dif-
ferent populations have demonstrated that a monozy-
gotic twin of a patient with MS has a higher risk (about
5–6 fold) ofMS than a dizygotic twin (Ebers, Sadovnick,
& Risch, 1995; Sadovnick et al., 1996). Collectively,
these findings suggest that MS is a complex disease and,
like other complex diseases, disease risk and possibly
disease severity are affected by multiple genetic factors.
The human leukocyte antigen (HLA) region is the pri-
mary region that has repeatedly shown significant as-
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this region revealed that the HLADRB1∗1501 allele and
the HLADRB1∗1501-DQA1∗0102-DQB1∗0602 haplo-
type influence disease risk (Fogdell, Hillert, Sachs, &
Olerup, 1995; Zamani et al., 1995). However, polymor-
phisms in the HLA region only explain approximately
half of the genetic contribution to MS (McElroy & Ok-
senberg, 2008). Recent investigations have identified a
broad spectrum of non-HLA genes that apparently in-
fluence MS risk in different populations (Alcina et al.,
2009; Ramagopalan, Anderson, Sadovnick, & Ebers,
2007; Shahbazi et al., 2009, 2010).
CD24 is one of the non-HLA genes suggested to con-
tribute to the pathogenesis of MS (Bai et al., 2004). It is
a glycosylphosphatidylinositol (GPI)-linked cell surface
glycoprotein expressed in a broad range of hematopoi-
etic system cells, including T cells (Zhou, Wu, Nielsen,
& Liu, 1997), B cells (Liu et al., 1992), macrophages,
and neutrophils (Herna´ndez-Campo et al., 2007). It
is also known that CD24 is abundantly expressed in
CNS cells such as astrocytes and microglia (Zhou
et al., 2003). CD24 contributes to the pathogenesis of
MS through several mechanisms, including expansion
of autoreactive T cells in the target organ and regulation
of homeostatic proliferation (Bai et al., 2004). More-
over, it has been shown that CD24 mediates a CD28-
independent costimulatory pathway that can induce the
activation of CD4 and CD8 T cells (De Bruijn, Peter-
son, & Jackson, 1996). CD24 is also required for the in-
duction of experimental autoimmune encephalomyelitis
(EAE), an animal model of MS (Liu et al., 2007). Hu-
man CD24 mRNA has a 0.24-kb open reading frame
(ORF) and a 1.8-kb 39 untranslated region (UTR). A
replacement of C with T in the coding region of CD24
at nucleotide position 170 from the translation start site
(P170) results in the neoconservative substitution of ala-
nine for valine preceding the putative cleavage site for
the CD24 GPI anchor (Wang et al., 2007). Generally,
it seems that single nucleotide polymorphisms (SNPs)
in coding regions or regulatory sites of genes can have
large impacts on gene expression and function. There-
fore, they can be considered a major cause of disease
outcome.
To understand the importance of the CD24 SNP in
influencing the relative risk of MS, a few studies were
conducted in different populations to determine the as-
sociation of the CD24 SNP with MS (Liu & Zheng,
2007; Ronaghi, Vallian, & Etemadifar, 2009; Zhou
et al., 2003). However, a limited number of studies have
been published regarding the expression of CD24 at
protein or mRNA levels in MS patients. In the present
study, we used a polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) method
to investigate the contribution of the CD24 SNP to MS
disease risk and severity in IranianMS patients. In addi-
tion, we compared CD24 mRNA expression in MS pa-
tients and healthy controls using TaqMan quantitative
real-time PCR.
MATERIALS AND METHODS
Each participant in the patient and control groups gave
their informed consent before sample collection, and
the study was performed according to the instructions
of the local ethics committee. A total of 120 unrelated
Iranian relapsing-remitting multiple sclerosis (RRMS)
patients (mean age: 38.2 ± 8.5 years, range: 21–61),
diagnosed according to the recommended diagnostic
criteria for MS [the McDonald criteria (McDonald
et al., 2001)], were studied in the Department of
Neurogenetics of the Iranian Center of Neurological
Research. All these patients were treated with interferon
beta (β). Sixty-one patients received 30 µg of interferon
β1a intramuscularly once weekly (Avonex), 38 patients
received 250 µg of interferon β1b subcutaneously every
other day (Betaferon), and the remaining 21 patients
received 44 µg of interferon β1a subcutaneously three
times weekly (Rebif). An expert neurologist clinically
assessed the patients, and clinical information, includ-
ing the Expanded Disability Status Scale (EDSS), a
method of quantifying the degree of disability in MS
(Kurtzke, 1983), and the global Multiple Sclerosis
Severity Score (MSSS), a method that provides a novel
approach by relating EDSS scores to the distribution of
disability in patients with comparable disease durations
(Roxburgh et al., 2005), was recorded. One hundred
and twenty age, sex, and geographically matched
healthy volunteers (mean age: 37.2 ± 7.8 years, range:
22–65) with no history of autoimmune or inflammatory
disorders were randomly selected to serve as controls.
Blood samples were collected in 5% ethylenediaminete-
traacetic acid (EDTA) tubes from patients and controls
for RNA and DNA extraction.
DNA Extraction and CD24 SNP Genotyping
Genomic DNA was extracted from peripheral blood
samples (10 mL peripheral blood in 5% EDTA) using a
modified salting out method (Miller, Dykes, & Polesky,
1988). CD24 SNP genotyping was performed using the
PCR with subsequent RFLP analysis. A C to T sub-
stitution in the coding region of CD24 at nucleotide
position 170 from the translation start site (P170) cre-
ates a BstX1 restriction site that can be used to dif-
ferentiate alleles in RFLP analysis. PCR reactions were
performed in a thermal cycler (Eppendorf, UK) using
previously described primers: forward: 5′-TTGTTG-
CCACTTGGCATTTTTGAGGC-3′ and reverse: 5′-
GGATTGGGTTTAGAAGATGGGGAAA-3′ (NCBI
Reference Sequence: NW 001838990.2; Zhou et al.,
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2003). The PCR conditions were as follows: 5 min at
94◦C followed by 94◦C for 30 s, 62◦C for 30 s, and
72◦C for 45 s, repeated for 35 cycles, and finally 5 min
at 72◦C as the final extension. The predicted CD24
PCR fragment is 453-bp long. PCR products were di-
gested with BstX1 restriction endonuclease under opti-
mal conditions. PCR products of allele T were cut into
two small fragments (317 and 136 bp), whereas allele
C remained undigested (453 bp). The products were
electrophoresed in a 2% agarose gel and visualized using
ethidium bromide.
RNA Extraction and Quantitative Reverse
Transcriptase PCR (RT-PCR)
Total RNA was isolated from peripheral blood mononu-
clear cells (PBMCs) using the Trizol (Invitrogen)
method. The RNA concentration was measured using
a NanoDrop ND 1000 (Nanodrop Technologies Inc.,
Wilmington, Delaware, USA). The 260/280 ratio was
above 1.75 for all samples. Total RNA (400 ng) was
reverse transcribed with the QuantiTect Reverse Tran-
scriptase kit (Qiagen, catalog no. 205311). Quantitative
real-time PCR was performed using a Corbett Rotor-
Gene 6000 with the QuantiFast Probe PCR kit (Qiagen,
catalog no. 204254) in accordance with the manufac-
turer’s instructions. All primers and probes were
synthesized by Metabion international AG (Germany).
The following primers and probe that we designed were
used to quantify CD24 mRNA expression: forward
primer: 5′-ACCCACGCAGATTTATTCCA-3′ and
reverse primer: 5′-CGAAGAGACTGGCTGTTGAC-
3′ and probe: 5′-Fam-ATCCAACTAATGCCACCA-
CCAAGGCG-BHQ-1-3′. The glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) gene was am-
plified to serve as an endogenous reference (internal
control gene) with the following primers and probe:
forward primer: 5′-CCCACTCCTCCACCTTTG-3′
and reverse primer: 5′-TCATACCAGGAAATGAGC-
TTGAC-3′ and probe: 5′-Fam-CTGGCATTGCCC-
TCAACGACCA-BHQ-1-3′. Real-time PCR was per-
formed using optimal conditions. cDNA product (2
µL) was amplified using the QuantiFast Probe PCR
kit according to the manufacturer’s instructions with
the following program: 3 min at 95◦C as a PCR initial
activation step followed by two-step cycling at 95◦C for
3 s and 60◦C for 30 s, repeated for 40 cycles. A 1/1,000
dilution of pooled cDNA from healthy controls was
included in each assay as a calibrator. Each sample was
assayed in triplicate. The real-time PCR efficiency was
between 92% and 105% in all PCR runs. A comparative
threshold cycle (CT), calculated by plotting the Ct
(cycle number) using rotor-gene 6 program (version
6.1), was used to determine gene expression relative
to the calibrator. In short, average relative expression
was determined by the comparative method (2−Ct),
which involves normalization to the endogenous refer-
ence GAPDH and examination relative to a calibrator
(Livak & Schmittgen, 2001). To validate the Ct
calculation, tenfold serial dilutions of cDNA of the
target and reference genes were amplified using primers
and fluorogenic probes for CD24 and GAPDH. To
calculate the amplification efficiencies of the target and
reference genes, a plot of the cDNA dilution versus CT
was made. The amplification efficiencies of CD24 and
GAPDH were 0.97 and 0.95 respectively.
Statistical Analysis
All data were entered into a database and analyzed
using SPSS version 16 for Windows. Deviation from
the Hardy–Weinberg assumption was checked for each
polymorphism in patients and controls separately. Com-
parisons of the frequencies of the CD24 alleles and
genotypes between the patient and control groups were
carried out using a chi-square test with Yates’ correc-
tion. To assess disease severity in MS patients, the
global MSSS was calculated, and normal distribution
was checked using the Kolmogorov–Smirnov test. One-
way analysis of variance (ANOVA) and Tukey’s honestly
significant difference (HSD) post hoc test were used to
compare the global MSSS in each genotype in MS pa-
tients and to determine which groups differ from each
other. Relative expression was determined by the com-
parative method (2−Ct), and an independent student
t-test was used to compare Ct between two groups. A
p value <.05 was considered statistically significant.
RESULTS
The Inﬂuence of CD24 Genotype on MS
Susceptibility and Severity
The distribution of CD24 allele and genotype frequen-
cies in MS patients and healthy controls is shown in
Table 1. Three different genotypes could be de-
tected after PCR amplification and BstX1 digestion
of total genomic DNA. The genotype distribu-
tion of this polymorphism did not deviate from the
Hardy–Weinberg equilibrium in patient and con-
trol groups. A comparison of genotype frequencies
between MS patients and controls indicates that
the CD24v/v genotype was significantly more fre-
quent in MS patients than in controls (OR = 3.500,
pc = .004). This result suggests that the CD24v/v
genotype may play a role in MS susceptibility.
MS disease severity is usually evaluated using EDSS,
but we used the global MSSS to assess disease sever-
ity because it combines disease duration with EDSS to
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TABLE 1. The distribution of CD24 allele and genotype frequencies in MS patients and healthy controls
MS patients Controls p value pc
a
OR (95% CI)b
Alleles nc = 240 n = 240
A 152 (63.3%) 175 (72.9%) .024 .031 0.642 (0.436–0.945)
V 88 (36.7%) 65 (27.1%) .024 .031 1.559 (1.058–2.291)
Genotypes Nd = 120 N = 120
CD24a/a 56 (46.7%) 63 (52.5%) .366 .4386 0.792 (0.477–1.314)
CD24a/v 40 (33.3%) 49 (44.5%) .229 .285 0.622 (0.365–1.062)
CD24v/v 24 (20%) 8 (6.7%) .002 .004 3.500 (1.503–8.150)
Note: p value < .05 considered statistically significant were showed in bold.
aThe two-tailed p value with Yates’ correction.
bOdds ratio (OR) with 95% confidence interval (CI).
cNumber of chromosomes.
dNumber of patients.
provide a better measurement of MS disease severity. A
comparison of the MSSS among different CD24 geno-
types in MS patients is shown in Tables 2 and 3. The
results showed a significant difference in the MSSS of
the three different genotypes (F = 4.824, p = .010).
Subsequent analysis using Tukey’s HSD post hoc test
(Table 3) revealed a statistically significant difference in
the MSSS between the CD24a/a and the CD24v/v geno-
type (p = .008). These data suggest that the CD24v/v
genotype may influence both disease susceptibility and
severity in Iranian MS patients.
Analysis of CD24 Gene Expression in MS
We investigated CD24 gene expression in PBMC from
patients with MS and controls. The amount of CD24
mRNA normalized to the endogenous reference and
relative to a calibrator was expressed as follows: Ct =
average (Ave.) CD24Ct – Ave. GAPDHCt, and Ct
= Ave. Ct – Ave. CtCalibrator. Finally, average relative
expression was determined by the comparative method
(2−Ct). A comparison of CD24 gene expression
between MS patients and healthy controls is shown in
Table 4. The results indicated a significant difference
in the Ct between MS patients and controls (p =
.00001). As shown in Table 4, when we calculated
the relative amount of CD24 mRNA, it showed a





MSSS SEa Nb F p value
CD24a/a 4.67 0.30 56
CD24a/v 5.50 0.39 40 F (2, 117) = 4.824 .010
CD24v/v 6.46 0.52 24
Note: p value < .05 considered statistically significant were
showed in bold.
aStandard error of the mean.
bNumber of patients.
1.7-fold upregulation of CD24 mRNA in MS patients
compared with controls. To investigate the relative
expression of CD24 among different CD24 genotypes
in MS patients, we used the Ct (Figure 1). This
result did not show any significant difference among
the three CD24 SNP genotypes (F = 0.268, p = .765).
DISCUSSION
Polymorphisms in the HLA region explain approx-
imately half of the genetic contribution to MS
(McElroy & Oksenberg, 2008). Several genome-wide
association studies have shown the possibility of con-
tributions from non-HLA genes to the pathogenesis of
MS. One of these studies suggested a linkage disequilib-
rium in distal 6q, where an interesting candidate gene,
CD24, is located (Haines et al., 1996). It is well es-
tablished that SNPs in immune-related genes influence
host susceptibility to autoimmune disorders such as MS
(McElroy & Oksenberg, 2008; Zhou et al., 2003). Non-
synonymous SNPs altering amino acid sequences are
believed to be responsible for most well-known disease
susceptibilities and phenotypic variations and have been
emphasized as suitable targets in candidate gene screens
(Tabor, Risch, & Myers, 2002). Several studies previ-
ously conducted in different populations showed an as-
sociation of a CD24 SNP withMS (Liu & Zheng, 2007;
TABLE 3. Comparison of the MSSS among different CD24
genotypes in MS patients using Tukey’s HSD test
CD24 genotypes
MSSS mean
difference SEa p value
CD24a/a and CD24a/v −0.83 0.49901 .224
CD24a/a and CD24v/v −1.79 0.58809 .008
CD24a/v and CD24v/v −0.96 0.62238 .275
Note: p value< .05 considered statistically significant were showed
in bold.
aStandard error of the mean.
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TABLE 4. Comparison of CD24 gene expression between MS patients and healthy controls
Cta Ctc
Case or control N Mean SEb Mean SE Rd = 2−Ct RMS/RConte
MS patients 120 7.2551 0.1508 –3.6321 0.1703 12.3985 1.7116
Controls 120 8.0888 0.1145 –2.8567 0.1456 7.2435
p value 1×10−5
Note: p value < .05 considered statistically significant were showed in bold.
aAve. CD24Ct – Ave. GAPDHCt.
bStandard error of the mean.
cAve. Ct – Ave. CtCalirator (1/1,000 dilution of pooled cDNA from healthy controls).
dRelative amount of the target.
eThe ratio of the relative amount of target in MS patients to the relative amount of target in healthy controls.
Ronaghi et al., 2009; Zhou et al., 2003). However, a lim-
ited number of studies have been published regarding
the expression of CD24 protein and mRNA in PBMCs
in MS.
In this study, we investigated both the contribution
of the CD24 SNP to the relative risk of MS and also, for
the first time, CD24 mRNA expression in Iranian MS
patients. Our findings showed that the CD24v/v geno-
type was significantly more frequent inMS patients (OR
= 3.500, pc = .004); these findings were consistent with
the study previously conducted by Zhou et al. (2003), in
which a significant association was found between MS
and the CD24v/v genotype (6.3% of the controls carried
the CD24v/v genotype vs. 13.2% in MS, p = .023; Zhou
et al., 2003). Moreover, our data were also similar to
those from other studies carried out in Spanish and
FIGURE 1. The comparison of CD24 relative expression among
different CD24 SNP genotypes in MS patients shows no statisti-
cally significant difference in CD24 gene expression among dif-
ferent genotypes. Ct: Ave. Ct – Ave. CtCalibrator.
Iranian populations (Otaegui et al., 2006; Ronaghi et
al., 2009). In 2006, Goris et al. investigated the asso-
ciation of the CD24a/v genotype with susceptibility and
progression of MS in a relatively broad population from
Belgium and the UK, and their results did not show an
association of the CD24a/v genotype with MS. Thus,
our findings confirmed pervious data (Goris et al., 2006;
Otaegui et al., 2006; Ronaghi et al., 2009), suggesting
that CD24v/v, but not CD24a/v or CD24a/a, may act as
a modifier of MS risk. To investigate the correlation of
CD24 genotypes and MS disease severity, we used the
global MSSS instead of EDSS for a better measurement
of disease severity and progression. Our findings re-
vealed that there is a statistically significant difference in
the MSSS between CD24a/a and CD24v/v genotypes (p
= .008, Table 3). This finding indicates that the CD24v/v
genotype is associated with both disease susceptibil-
ity and severity in Iranian MS patients. Zhou et al.
(2003) also reported that the severity of MS in 50% of
the CD24v/v patients reached an EDSS of 6.0 within
5 years, whereas 50% of the CD24a/a and CD24a/v
patients reached that milestone in 13 and 16 years,
respectively. Therefore, it can be concluded that MS
patients with the CD24v/v genotype have greater disease
severity and more rapid progression than those with
the CD24a/a and CD24a/v genotypes. Consequently, it
can be suggested that MS patients bearing the CD24v/v
genotype need better guidelines for optimal treatment
than those with the CD24a/a and CD24a/v genotypes.
To date, a limited number of studies have investi-
gated CD24 expression at the protein or mRNA level
in PBMCs (Wang et al., 2007; Zhou et al., 2003). We
used quantitative TaqMan real-time PCR to detect
CD24 mRNA expression. A comparison of CD24 gene
expression between patients and controls showed that
the expression of CD24 mRNA in MS patients was 1.7
times more than that in controls. Although the mRNA
level of MS patients with the CD24v/v genotype was
slightly higher than that of patients with CD24a/a and
CD24a/v genotypes, there was no significant difference
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in the mRNA level between the different CD24 geno-
types among MS patients (F = 0.268, p = .765). Our
findings were inconsistent with the study conducted
by Zhou et al. (2003) regarding CD24 expression at
the protein level by two-color flow cytometry. Their
results indicated that regardless of genotype, CD24 is
expressed on both T cells and non-T cells, but T cells
fromCD24a/a patients expressed sixfold less cell-surface
CD24 than did T cells from CD24v/v patients (Zhou
et al., 2003). The difference in the distribution of blood
cellularities in MS patients and healthy controls and
also the differences caused in this cellularity by the
treatment of MS with interferon β may explain this
inconsistency. CD24 is a GPI-linked protein with 32
amino acids in the mature human protein. It has been
speculated (Zhou et al., 2003) that the replacement
of alanine with valine at amino acid 31, immediately
preceding the putative cleavage site for the GPI anchor,
may increase the efficiency of cleavage and result in an
increased expression of CD24v/v on the cell surface.
It seems the inconsistency that exists between CD24
expression at the protein and the mRNA level could
likely result from processing of the CD24 protein itself
that leads to the expression of CD24 protein on T cells
with different efficiencies.
In conclusion, our findings suggest that the CD24v/v
genotype may influence both MS disease risk and sever-
ity in Iranian MS patients. High disease severity mea-
sured by the MSSS in the CD24v/v patients may suggest
that they need better guidelines for optimal treatment.
Moreover, our data showed that CD24 mRNA expres-
sion was 1.7 times more in MS patients compared with
controls. CD24 mRNA expression in CD24v/v patients
was slightly more than that in CD24a/a and CD24a/v
MS patients, but this was not a large enough increase
to be significantly different. It appears that the high dis-
ease severity provided by the CD24v/v genotype may be
caused by post-mRNA processing on the CD24 protein
and alterations to the efficacy of T cells. As our study
was limited by the small sample size, it would be great
that our finding be extended and confirmed in other
populations and a larger sample size.
Declaration of interest: The authors report no con-
flict of interest. The authors alone are responsible for the
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